Supplementary Figure. Time From Receipt of Nirsevimab to Symptom Onset Among Eligible Children in Their First or Second Respiratory Syncytial Virus Season Who Had Medically Attended Acute Respiratory Illness, by Respiratory Syncytial Virus Test Result — Yukon-Kuskokwim Region, Alaska, October 23, 2023–June 30, 2024

Details

• Alternative Title:
  Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children — Yukon-Kuskokwim Delta Region, Alaska, October 2023–June 2024: Supplementary Figure. Time From Receipt of Nirsevimab to Symptom Onset Among Eligible Children in Their First or Second Respiratory Syncytial Virus Season Who Had Medically Attended Acute Respiratory Illness, by Respiratory Syncytial Virus Test Result — Yukon-Kuskokwim Region, Alaska, October 23, 2023–June 30, 2024
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.).
• Description:
  Supplementary Figure. Morbidity and Mortality Weekly Report, Vol. 73, No. 45, November 14, 2024
• Subjects:
  Disease Control Disease Notification Public Health Public Health Surveillance Respiratory Syncytial Virus Infections / Prevention & Control
• Source:
  MMWR: Morbidity and Mortality Weekly Report 2024; v. 73, no. 45
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Document Type:
  Journal Article
• Genre:
  Tables ; Statistics
• Place as Subject:
  United States
• Pages in Document:
  1 pdf page
• Volume:
  73
• Issue:
  45
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:e8c3e01b8f7dd111d0347beaf955cd04ae53c65c9f7fbf8aef8e9f9291bbc1b627fad020a672284b676122d55c158bd8e149394b3a4c5134889ed0c219ccc295
• Download URL:
  https://stacks.cdc.gov/view/cdc/168889/cdc_168889_DS1.pdf
• File Type:
  [PDF - 237.79 KB ]